This Week in Cardiology

De: Medscape
  • Resumen

  • This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.
    Copyright 2019, Medscape
    Más Menos
Episodios
  • May 02, 2025 This Week in Cardiology
    May 2 2025

    The FDA approval of TAVR for asymptomatic AS, digital health, subcutaneous vs transvenous ICD, and cryptogenic stroke in young adults are discussed by John Mandrola, MD.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I FDA announces approval for TAVR in pts with asymptomatic AS

    • Edwards Press Release https://www.edwards.com/newsroom/news/2025-05-01-edwards-tavr-receives-fda-approval-for-patients-with-asymptomatic-severe-aortic-stenosis
    • Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis (EARLY TAVR) https://www.nejm.org/doi/full/10.1056/NEJMoa2405880
    • EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec
    • Asymptomatic Aortic Stenosis: 'Time to Act' or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9

    II PPG that Can Distinguish source of Tachycardia

    • Machine-learning guided differentiation between photoplethysmography waveforms of supraventricular and ventricular origin https://doi.org/10.1016/j.cmpb.2025.108798

    III PRAETORIAN -XL trial

    • Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL Trial https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074576
    • Subcutaneous or Transvenous Defibrillator Therapy (PRAETORIAN trial) https://www.nejm.org/doi/full/10.1056/NEJMoa1915932
    • Subcutaneous or Transvenous Defibrillator Therapy Letter to Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917
    • The PRAETORIAN Trial: Guarded Approach to Subcutaneous ICD Best https://www.medscape.com/viewarticle/937156

    IV Stroke in Young People

    • Burden of Modifiable Risk Factors in Young-Onset Cryptogenic Ischemic Stroke by High-Risk Patent Foramen Ovale https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.049855
    • Migraine: A Key Factor in Young Adults With Unexplained Stroke https://www.medscape.com/viewarticle/migraine-key-factor-young-adults-unexplained-stroke-2025a10009jj
    • U.S. stroke rate declining in adults 75 and older, yet rising in adults 49 and younger ASA statement https://newsroom.heart.org/news/u-s-stroke-rate-declining-in-adults-75-and-older-yet-rising-in-adults-49-and-younger
    • Increasing stroke in the young https://doi.org/10.1016/j.ajpc.2020.100085

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net

    Más Menos
    30 m
  • Apr 25 2025 This Week in Cardiology
    Apr 25 2025

    AI and ECGs, novel ways to treat hypertension, combined lipid-lowering therapy after myocardial infarction, PFA and silent stroke, a move toward accountability in AF ablation, and pacing issues in TTVR are the topics John Mandrola, MD, discusses in this week's podcast.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I Help with ECGs in the ED

    AI Shows Promise for Rapid NSTEMI Diagnosis

    https://www.medscape.com/viewarticle/ai-shows-promise-rapid-nstemi-diagnosis-2025a10009pw

    • Buscher et al https://doi.org/10.1093/eurheartj/ehaf254

    II A Novel way to Treat HTN

    A Pacemaker to Control BP Gets FDA Breakthrough Designation

    https://www.medscape.com/viewarticle/pacemaker-control-bp-gets-fda-breakthrough-designation-2025a10009t3

    • JAHA paper https://www.ahajournals.org/doi/10.1161/JAHA.120.020492
    • Backbeat https://clinicaltrials.gov/study/NCT06059638

    III Type of PFA may matter for Silent Cerebral Lesions

    • Paper https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013719

    IV Accountability coming to US AF ablation

    • Heart Rhythm Society Releases a Document on Establishing Centers of Excellence for AF ablation -- Press Release https://www.hrsonline.org/news/new-white-paper-on-atrial-fibrillation-centers-of-excellence/

    V Pacing in Patients with Undergoing Transcatheter Tricuspid Valve Replacement

    • Paper https://doi.org/10.1016/j.hrthm.2025.02.004

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net

    Más Menos
    28 m
  • Apr 18 2025 This Week in Cardiology
    Apr 18 2025

    The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week’s podcast.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I FAME 3 at Five Years

    Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4

    • Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299
    • Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770
    • 5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057

    II TAVR in Low-Risk Patients at 5 years

    5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients

    https://www.medscape.com/viewarticle/5-year-tavr-surgery-outcomes-similar-low-risk-patients-2025a10007zl

    • EVOLUT Low-Risk 5 years https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004
    • EVOLUT Editorial – We're Halfway There
      https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428
    • PARTNER 3 Low-Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2307447
    • NOTION at 5 years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606

    III The Matter of Pacemakers After TAVI

    • JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028
    • Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals

    IV Mavacamten Looks to Have Specific Indications

    • EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link
    • VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050
    • BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/

    FINAL THOUGHTS

    • PRAGUE 25 https://bmjopen.bmj.com/content/12/6/e056522

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net

    Más Menos
    24 m
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre This Week in Cardiology

Calificaciones medias de los clientes
Total
  • 5 out of 5 stars
  • 5 estrellas
    5
  • 4 estrellas
    0
  • 3 estrellas
    0
  • 2 estrellas
    0
  • 1 estrella
    0
Ejecución
  • 5 out of 5 stars
  • 5 estrellas
    5
  • 4 estrellas
    0
  • 3 estrellas
    0
  • 2 estrellas
    0
  • 1 estrella
    0
Historia
  • 5 out of 5 stars
  • 5 estrellas
    5
  • 4 estrellas
    0
  • 3 estrellas
    0
  • 2 estrellas
    0
  • 1 estrella
    0

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Ordenar por:
Filtrar por:
  • Total
    5 out of 5 stars
  • Ejecución
    5 out of 5 stars
  • Historia
    5 out of 5 stars

recommend to colleagues

Dr Mandrola delivers excellent updates on recent publications. The podcast is just the thing for a commute: not too superficial, not too detailed, and do a great job placing the new clinical advances in the context of contemporary practice.

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.

Has calificado esta reseña.

Reportaste esta reseña

  • Total
    5 out of 5 stars
  • Ejecución
    5 out of 5 stars
  • Historia
    5 out of 5 stars

EP is not about the money -love this statement

I absolutely love listening to this podcast and feel I practice medicine very similarly. I love your critical review of studies as it brings these areas to light. I especially loved your comment at the end of this podcast discussing the reasoning to go into EP. I agree with your reasons, and consider them the same for most fields of medicine, especially any in cardiology, which I practice as a PA in and have for 14 years. Going into medicine just for the money should never be the reason as it will only lead to frustration and burnout. Thank you for your honest reviews and feedback each week.

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.

Has calificado esta reseña.

Reportaste esta reseña

  • Total
    5 out of 5 stars
  • Ejecución
    5 out of 5 stars
  • Historia
    5 out of 5 stars

Muy informativo

Me gusta el escepticismo del Dr Mandrola. Habla de su objetividad y su compromiso con la ciencia bien hecha

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.

Has calificado esta reseña.

Reportaste esta reseña